Genia Turanova, Chief Investment Strategist for Game-Changing Stocks and Fast-Track Millionaire, is a financial writer and money manager whose experience includes serving for more than a decade as a portfolio manager and Investment Committee member for a New York-based money management firm. Genia also researched, wrote and managed recommendations for several investment advisories. From 2011 to 2016, she served as Editor of the award-winning Leeb Income Performance newsletter. Genia also wrote for The Complete Investor, another award winner, from 2003 to 2016. During that time, Genia was responsible for several portfolios, including the "Income/Value" portfolio and the "FastTrack" portfolio. Genia's academic credentials include an MBA in Finance and Investments from the Zicklin School of Business, Baruch College in New York City. Genia is a CFA Charterholder.
Analyst Articles
Are you worried about a recession? I’m guessing that you are – but probably not so much as...
Read More
Are you worried about a recession? I’m guessing that you are – but probably not so much as to affect your spending (yet, anyway). On average, the American consumer is feeling just fine....
Read More
The oft-quoted law of unintended consequences is an intriguing concept. Let’s say you join a...
Read More
The oft-quoted law of unintended consequences is an intriguing concept. Let’s say you join a gym to lose weight — and you meet the love of your life there. That’s an unintended...
Read More
Market volatility is back. And it didn’t take long. From the low of the year set on July 24,...
Read More
Market volatility is back. And it didn’t take long. From the low of the year set on July 24, the CBOE Volatility Index — also known as the Fear Index or simply the VIX — doubled...
Read More
The oft-quoted law of unintended consequences is an intriguing concept. Let’s say you join a gym to lose weight – and you meet the love of your life there. That’s an unintended consequence. It works the other way, too. Let’s say you join a… Read More
Yes, it’s a race to the bottom. I’m not talking about the market. I’m referring...
Read More
Yes, it’s a race to the bottom. I’m not talking about the market. I’m referring to interest rates. After a couple of wild weeks, stocks — as measured by the S&P 500 –...
Read More
For Myriad Genetics (Nasdaq: MYGN), it’s once again all about GeneSight, the test used to determine the correct antidepressant for psychiatric patients. This time, the diagnostic biotech company disappointed the bulls after it reported financial results for the fourth quarter and fiscal year ended June… Read More
Yes, it’s a race to the bottom. I’m not talking about the market. I’m referring to interest rates. After a couple of wild weeks, stocks — as measured by the S&P 500 – are trading by only about 3% below their… Read More
By the time you read this, you must be well aware that something went wrong with the stock market...
Read More
By the time you read this, you must be well aware that something went wrong with the stock market rally. Over the last week, the trade war escalated, with the slapping of new tariffs on Chinese...
Read More
A few notable movers in today’s weak market… New Relic (Nasdaq: NEWR), a big-data cloud company, reported its first fiscal quarter results Tuesday after the close. While the company’s 30% revenue growth for the three months was better than its own guidance, New Relic… Read More
A second consecutive quarter of beating earnings targets has finally moved the needle for Paratek (Nasdaq: PRTK), the owner of newly approved (fall 2018) novel antibiotic Nuzyra. Shares are up more than 35% today at mid-session. The company, which reiterated its full-year revenue guidance for… Read More
